Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: J Public Econ. 2023 Mar 17;221:104860. doi: 10.1016/j.jpubeco.2023.104860

Table 4 –

Detailing Test: Within-DMA Total Utilization of Chronic Drugs

Dependent Variable: # of Prescriptions

Baseline ZIP3 level DMA x Qtr FE

(1) (2) (3)
A. Instrument=Share65+ *Post
Share65+*Post (DMA level) 0.111***
(0.033)
Share65+*Post (ZIP3 level) 0.087***
(0.027)
0.015
(0.026)
B. Instrument=High Elderly Share *Post
High Elderly Share*Post (DMA level) 0.003**
(0.002)
High Elderly Share*Post (ZIP3 level) 0.006*** 0.002
(0.002) (0.002)
Mean of Dep. Var. (pre- Part D) 0.10 0.10 0.10
Zipcode x Condition x Quarter Obs 67,495 67,495 67,495

Notes:

***

p<0.01,

**

p<0.05,

*

p<0.1. Clustered standard errors at the 3-digit ZIP code level; all specifications include qtr fixed effects, 3-digit ZIP code fixed effects, condition fixed effects. Col 1: same as Table 2, but for sample of ZIP codes that are uniquely matched to one DMA, elderly share computed at the DMA-level; Col 2: elderly share computed at 3-digit ZIP code level; Col 3: adds DMA x quarter fixed effects, elderly share computed at 3-digit ZIP code level. Includes the 50 drugs that advertised during the study period for 5 chronic conditions: depression, diabetes, hyperlipidemia, hypertension, and osteoporosis.